1. Home
  2. AARD vs MACI Comparison

AARD vs MACI Comparison

Compare AARD & MACI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AARD
  • MACI
  • Stock Information
  • Founded
  • AARD 2017
  • MACI 2024
  • Country
  • AARD United States
  • MACI United States
  • Employees
  • AARD N/A
  • MACI N/A
  • Industry
  • AARD Biotechnology: Pharmaceutical Preparations
  • MACI
  • Sector
  • AARD Health Care
  • MACI
  • Exchange
  • AARD Nasdaq
  • MACI NYSE
  • Market Cap
  • AARD 216.6M
  • MACI 221.3M
  • IPO Year
  • AARD 2025
  • MACI 2024
  • Fundamental
  • Price
  • AARD $7.74
  • MACI $10.23
  • Analyst Decision
  • AARD Strong Buy
  • MACI
  • Analyst Count
  • AARD 4
  • MACI 0
  • Target Price
  • AARD $31.50
  • MACI N/A
  • AVG Volume (30 Days)
  • AARD 113.5K
  • MACI 66.6K
  • Earning Date
  • AARD 01-01-0001
  • MACI 01-01-0001
  • Dividend Yield
  • AARD N/A
  • MACI N/A
  • EPS Growth
  • AARD N/A
  • MACI N/A
  • EPS
  • AARD N/A
  • MACI N/A
  • Revenue
  • AARD N/A
  • MACI N/A
  • Revenue This Year
  • AARD N/A
  • MACI N/A
  • Revenue Next Year
  • AARD N/A
  • MACI N/A
  • P/E Ratio
  • AARD N/A
  • MACI $43.79
  • Revenue Growth
  • AARD N/A
  • MACI N/A
  • 52 Week Low
  • AARD $7.74
  • MACI $9.95
  • 52 Week High
  • AARD $19.58
  • MACI $10.34
  • Technical
  • Relative Strength Index (RSI)
  • AARD N/A
  • MACI N/A
  • Support Level
  • AARD N/A
  • MACI N/A
  • Resistance Level
  • AARD N/A
  • MACI N/A
  • Average True Range (ATR)
  • AARD 0.00
  • MACI 0.00
  • MACD
  • AARD 0.00
  • MACI 0.00
  • Stochastic Oscillator
  • AARD 0.00
  • MACI 0.00

About AARD Aardvark Therapeutics Inc. Common Stock

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

About MACI MELAR ACQUISITION CORP. I

Melar Acquisition Corp I is a blank check company.

Share on Social Networks: